395 related articles for article (PubMed ID: 18258313)
1. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses.
Spurgers KB; Sharkey CM; Warfield KL; Bavari S
Antiviral Res; 2008 Apr; 78(1):26-36. PubMed ID: 18258313
[TBL] [Abstract][Full Text] [Related]
2. Nucleic acids-based therapeutics in the battle against pathogenic viruses.
Haasnoot J; Berkhout B
Handb Exp Pharmacol; 2009; 189(189):243-63. PubMed ID: 19048203
[TBL] [Abstract][Full Text] [Related]
3. Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses.
Lim TW; Yuan J; Liu Z; Qiu D; Sall A; Yang D
Curr Opin Mol Ther; 2006 Apr; 8(2):104-7. PubMed ID: 16610761
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide-based antiviral strategies.
Schubert S; Kurreck J
Handb Exp Pharmacol; 2006; 173(173):261-87. PubMed ID: 16594620
[TBL] [Abstract][Full Text] [Related]
5. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
Wagner A; Bock CT; Fechner H; Kurreck J
Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
[No Abstract] [Full Text] [Related]
6. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers.
Stein DA
Curr Pharm Des; 2008; 14(25):2619-34. PubMed ID: 18991679
[TBL] [Abstract][Full Text] [Related]
7. Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells.
Dutkiewicz M; Ojdowska A; Kuczynski J; Lindig V; Zeichhardt H; Kurreck J; Ciesiołka J
PLoS One; 2015; 10(8):e0136395. PubMed ID: 26308932
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
9. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.
Deas TS; Binduga-Gajewska I; Tilgner M; Ren P; Stein DA; Moulton HM; Iversen PL; Kauffman EB; Kramer LD; Shi PY
J Virol; 2005 Apr; 79(8):4599-609. PubMed ID: 15795246
[TBL] [Abstract][Full Text] [Related]
11. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
12. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
13. RNA-based viral immunity initiated by the Dicer family of host immune receptors.
Aliyari R; Ding SW
Immunol Rev; 2009 Jan; 227(1):176-88. PubMed ID: 19120484
[TBL] [Abstract][Full Text] [Related]
14. Safety of antisense oligonucleotide and siRNA-based therapeutics.
Chi X; Gatti P; Papoian T
Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
[TBL] [Abstract][Full Text] [Related]
15. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis.
Vickers TA; Koo S; Bennett CF; Crooke ST; Dean NM; Baker BF
J Biol Chem; 2003 Feb; 278(9):7108-18. PubMed ID: 12500975
[TBL] [Abstract][Full Text] [Related]
16. Antisense and RNA interference approaches to target validation in pain research.
Kurreck J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
[TBL] [Abstract][Full Text] [Related]
17. Oligonucleotide-based strategies to inhibit human hepatitis C virus.
Martinand-Mari C; Lebleu B; Robbins I
Oligonucleotides; 2003; 13(6):539-48. PubMed ID: 15025918
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.
Jairath S; Vargas PB; Hamlin HA; Field AK; Kilkuskie RE
Antiviral Res; 1997 Feb; 33(3):201-13. PubMed ID: 9037376
[TBL] [Abstract][Full Text] [Related]
19. Types of RNA therapeutics.
Goleij P; Babamohamadi M; Rezaee A; Sanaye PM; Tabari MAK; Sadreddini S; Arefnezhad R; Motedayyen H
Prog Mol Biol Transl Sci; 2024; 203():41-63. PubMed ID: 38360005
[TBL] [Abstract][Full Text] [Related]
20. Strand-specific silencing of a picornavirus by RNA interference: evidence for the superiority of plus-strand specific siRNAs.
Schubert S; Rothe D; Werk D; Grunert HP; Zeichhardt H; Erdmann VA; Kurreck J
Antiviral Res; 2007 Mar; 73(3):197-205. PubMed ID: 17112603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
